Alterations of Serum Levels of BDNF-Related miRNAs in Patients with Depression by Li, You-Jie et al.
 
Alterations of Serum Levels of BDNF-Related miRNAs in Patients
with Depression
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Li, You-Jie, Mei Xu, Zong-Hua Gao, Ya-Qi Wang, Zhen Yue,
Yan-Xia Zhang, Xin-Xin Li, Can Zhang, Shu-Yang Xie, and Ping-
Yu Wang. 2013. Alterations of serum levels of bdnf-related mirnas
in patients with depression. PLoS ONE 8(5): e63648.
Published Version doi:10.1371/journal.pone.0063648
Accessed February 19, 2015 12:07:46 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11357497
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAAlterations of Serum Levels of BDNF-Related miRNAs in
Patients with Depression
You-Jie Li
1.,M e iX u
2., Zong-Hua Gao
3, Ya-Qi Wang
1, Zhen Yue
1, Yan-Xia Zhang
1, Xin-Xin Li
1,
Can Zhang
4, Shu-Yang Xie
1*, Ping-Yu Wang
1,5*
1Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, ShanDong, P.R. China, 2Department of Psychiatry of Yantai Fushan District
People’s Hospital, YanTai, ShanDong, P.R. China, 3Department of Chemistry, Binzhou Medical University, YanTai, ShanDong, P.R. China, 4Genetics and Aging Research
Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, United States of America, 5Department of
Epidemiology, Binzhou Medical University, YanTai, ShanDong, P.R. China
Abstract
Depression is a serious and potentially life-threatening mental disorder with unknown etiology. Emerging evidence shows
that brain-derived neurotrophic factor (BDNF) and microRNAs (miRNAs) play critical roles in the etiology of depression. Here
this study was aimed to identify and characterize the roles of BDNF and its putative regulatory miRNAs in depression. First,
we identified that miR-182 may be a putative miRNA that regulates BDNF levels by bioinformatic studies, and characterized
the effects of miR-182 on the BDNF levels using cell-based studies, side by side with miR-132 (a known miRNA that regulates
BDNF expression). We showed that treatment of miR-132 and miR-182 respectively decreased the BDNF protein levels in a
human neuronal cell model, supporting the regulatory roles of miR-132 and miR-182 on the BDNF expression. Furthermore,
we explored the roles of miR-132 and miR-182 on the BDNF levels in depression using human subjects by assessing their
serum levels. Compared with the healthy controls, patients with depression showed lower serum BDNF levels (via the
enzyme-linked immunosorbent assays) and higher serum miR-132 and miR-182 levels (via the real-time PCR). Finally, the
Pearson’s (or Spearman’s) correlation coefficient was calculated to study whether there was a relationship among the Self-
Rating Depression Scale score, the serum BDNF levels, and serum BDNF-related miRNA levels. Our results revealed that there
was a significant negative correlation between the SDS scores and the serum BDNF levels, and a positive correlation
between the SDS scores and miR-132 levels. In addition, we found a reverse relationship between the serum BDNF levels
and the miR-132/miR-182 levels in depression. Collectively, we provided evidence supporting that miR-182 is a putative
BDNF-regulatory miRNA, and suggested that the serum BDNF and its related miRNAs may be utilized as important
biomarkers in the diagnosis or as therapeutic targets of depression.
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Introduction
Depression is a serious and potentially life-threatening clinical
mental disorder with unknown etiology. In some cases, it shows
severe and persistent symptoms, and insidiously impacts on the life
quality of the patients [1]. Depression is sometimes associated with
impaired recovery from a number of medical conditions, including
stroke, hip fracture, and myocardial infarction [2–4]. Gender has
also been found to associate with depression, with women
demonstrating higher levels of depressed mood compared with
men [5,6]. Though the molecular and cellular mechanisms of
depression have still not been completely elucidated, it was
suggested that nearly 50% of the risk for depression is contributed
to genetic factors [7]. Furthermore, emerging evidence shows that
changes in gene expression play crucial roles in the pathogenesis of
depression [8,9]. The bdnf gene is one of the most essential genes
which are involved in the pathophysiology of several mental
disorders, including depression. The BDNF protein is a neurotro-
phin and plays essential roles in neuronal development and
plasticity. Decreased BDNF protein has been suggested to affect
the pathology of major depressive disorder (MDD) [10,11]. Bdnf
has also been suggested as a susceptibility gene for MDD and
schizophrenia (SCZ), especially in a subgroup of patients with
schizophrenia and a lifetime history of depressive symptoms.
Moreover, a polymorphism in the bdnf gene is associated with
depression-related traits in several independent studies [12–15].
Because it is difficult to assess the BDNF levels directly from
patients’ brain, increasing effort has focused on measuring the
BDNF levels in the blood. The serum BDNF levels were found to
be lower in depressed patients compared with control subjects
[16]. Interestingly, the serum BDNF levels were increased
following the treatment of antidepressant medications [17],
suggesting that the serum BDNF levels could be as a surrogate
biomarker for determining both the depression status and the
efficacy of antidepressant treatment.
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characterizing the factors that modulate BDNF levels, one of
which that has been recently intensively studied is microRNA
(miRNA). miRNAs are endogenous small non-coding RNAs that
regulate various gene expression at post-transcriptional levels
through targeting mRNAs for cleavage or translational repression
[18]. miRNAs are essential for different cellular processes,
including metabolism, differentiation and apoptosis in both
animals and plants [19–21]. Increasing evidence suggests a critical
role of miRNAs in the pathogenesis of neuropsychiatric disorders,
including depression. For example, two polymorphisms, located in
pre-miR-182 and pre-miR-30e, were associated with the increased
risk of the major depressive disorder [22,23]. Another study
showed that miR-124a, one of the most abundant miRNAs in the
brain [24], may contribute to depression by suppressing the
expression of glucocorticoid receptor, the activation of which
interferes with the hippocampal neurogenesis [25]. In addition, a
study showed that either up-regulation of miR-16 in raphe or
down-regulation of miR-16 in locus coeruleus induced behavioral
responses using depressive mouse models [26]. In summary, these
studies clearly showed that miRNAs are involved in the etiology of
depression by regulating their targeting genes.
Considering the important roles of BDNF and miRNAs in the
pathogenesis of depression, our current study was aimed at
identifying the novel miRNAs that regulate serum BDNF levels,
and characterizing the relationship between miRNAs and
depression. First, in a neuronal cell-based model, we used miR-
132 as a positive control and confirmed that it regulated the
expression of BDNF as previous report [27]. We also found that
miR-182 was a novel putative miRNA that regulated the BDNF
expression through bioinformatic and cell-based functional studies.
Next, we measured the serum levels of BDNF, miR-132 and miR-
182 in human subjects with depression and controls. Our results
demonstrated that serum BDNF levels were decreased in
depressed patients compared with control subjects, consistent with
previous studies. We also found that the levels of miR-132 and
miR-182 were increased in patients compared with those in
healthy controls. Our results demonstrate that the serum BDNF
and its related miRNAs may be utilized as important biomarkers
for the diagnosis or as the therapeutic targets of depression.
Results
Clinical Characteristics of Patients and Controls
First, we characterized the demographic and clinical charac-
teristics of all the patients and controls that took part in this study
(Table 1). Forty patients with depression and forty controls
participated in the study. Notably, the patients in this study with
melancholic features showed observable psychomotor retardation
and all patients diagnosed with psychotic depression showed
mood-congruent delusions, like delusions of guilt, delusions of
poverty or nihilistic delusions. None of the patients with depression
in the present study met criteria for atypical depression or suffered
from hallucinations.
Lower Serum BDNF Levels in Patients with Depression
We next studied the serum BDNF levels in patients with
depression and controls by ELISA. Our results showed that the
mean serum BDNF levels in the patient samples were
20.0565.98 ng/ml, which were much lower than those in healthy
controls 25.2265.17 ng/ml (Table 1, Fig. 1A). This finding was
supported by a previous reported showing that the serum BDNF
levels were decreased in patients compared with control subjects
[16]. Thus, these independent studies suggest that the serum
BDNF levels could be utilized as a surrogate biomarker of
depression.
Higher Levels of BDNF-related miRNAs in Patients with
Depression
Next, we explored to identify and characterize putative
miRNAs that regulate BDNF protein levels. We utilized an
widely-utilized online miRNA analysis software, which provides a
comprehensive analysis to identify the targeting genes of specific
miRNAs (http://www.microrna.org/microrna/getMirnaForm.
do, or http://www.targetscan.org/index.html). We found that
the BDNF mRNA 39-untranslated regions (UTR) was targeted by
miR-182 through this computational analysis (Fig. 1B). As a
positive control, miR-132 was also investigated in this study, which
has been reported to regulate BDNF expression [27].
In our next set of experiments, we investigated the functional
roles of miR-182 in regulating the levels of BDNF using cell-based
models. After chemical synthesis of miRNAs, the human
neuroblastoma SH-SY5Y cells were transfected with miR-132 or
miR-182, and the BDNF expression was detected by western
blotting analysis. Our results showed that the BDNF levels were
decreased in miR-182-treated cells, as well as in miR-132-treated
cultures, compared with control treatment (Fig. 2A,B). Thus, our
results supported the roles of both miR-182 and miR-132 in
regulating the BDNF expression.
Furthermore, we investigated the serum levels of the novel
putative BNDF-regulating miR-182, along with miR-132, in our
characterized human subjects by real-time PCR. We found that
the serum miR-132 levels in patients with depression were
0.58610
3 copies/ml (n=40), which were significantly higher than
those in the serum of healthy controls (0.13610
3 copies/ml,
P,0.01, n=40, Table 1, Fig. 3A). In addition, the serum miR-182
levels in patients with depression were 0.02610
3 copies/ml
(n=40), which were also significantly higher than those in the
serum levels of healthy controls (P,0.01, Table 1, n=40, Fig. 3B).
Our results demonstrated that miR-182 was a novel putative
BNDF-regulating miRNA, which may be involved in the
pathogenesis of depression.
Relationship between the Serum Levels of BDNF and its
Regulatory miRNAs
We have identified that the serum BDNF levels were decreased
and the BDNF-related miRNAs including miR-182 and miR-132
were increased in human subjects with depression compared with
control subjects. Due to the reported role of miRNAs in negatively
regulating their targeting gene expression, we reasoned that there
might exist a direct negative relationship between the serum
BDNF levels and its-related miRNAs. To test this hypothesis, the
relationship between the serum levels of BDNF and its-related
miRNAs was examined by calculating Spearman’s correlation
coefficient. Our results showed a significant negative correlation
(Spearman rs=20.307, P=0.006) between the serum BDNF
levels and the miR-132 levels in patients with depression (n=40)
and controls (n=40, Fig. 4A). However, there was no significant
correlation (Spearman rs=0.098, P=0.385) between the serum
BDNF levels and the miR-182 levels in all patients (n=40) and
controls (n=40, Fig. 4B).
Relationship between SDS and the Serum Levels of
BDNF-related miRNAs
Finally, we studied whether the serum levels of miRNAs may be
applied in diagnosing depression. The relationship between the
serum levels of miRNAs and the Self-Rating Depression Scale
BDNF-Related miRNAs in Depression
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man’s) correlation coefficient. A significant negative correlation
was revealed (Pearson r=20.427, P=7.75E-05) between the
serum BDNF levels and the SDS scores in all subjects (n=80),
including 40 patients with depression and 40 controls (Fig. 5A). In
addition, there was a significant positive correlation (Spearman
rs=0.347, P=0.002) between the serum miR-132 levels and the
SDS scores in all subjects (n=80), including 40 patients with
depression and 40 controls (Fig. 5B). A significant positive
correlation (Spearman rs=0.242, P=0.030) was also found
between the serum miR-182 levels and the SDS scores in all
subjects (n=80, Fig. 5C). Thus, our results indicated that the
serum levels of miRNAs were statistically correlated with the SDS
scores, and suggested that their levels should be able to assist in the
diagnosis of depression.
Discussion
In current study, we characterized the roles of BDNF and its
related miRNAs in the pathogenesis of depression. BDNF is an
important member of the neurotrophin family of growth factors,
which induces stress in both animal models [28] and human
psychopathologies, including major depression, or posttraumatic
stress disorder [10,29]. We identified miR-132 and miR-182 as
BDNF regulatory miRNAs by bioinformatics, and functionally
validated their role in the negative regulation of the BDNF
expression using a human neuronal cell model. Then we further
explored the roles of BDNF and its related miRNAs in patients
with depression and control subjects. Our results showed that the
serum BDNF levels in patients with depression were significantly
decreased compared with controls. Interestingly, the serum levels
of miR-132 and miR-182 were increased in patients with
depression, compared with their controls. A negative relationship
between BDNF and miR-132 was found in serum of both patients
and controls. There was also a negative correlation between the
BDNF levels and the SDS scores in depressed patients and healthy
controls. Moreover, significant positive correlations were found
not only between the serum miR-132 level and SDS score, but also
between the serum miR-182 levels and the SDS scores in
depressed patients and healthy controls.
Identifying biomarkers and applying them in the diagnosis of
major depressive disorder have remained a goal of clinicians and
scientists for many decades. Karege F. and colleagues [30]
demonstrated that cortical BDNF levels were consistent with
serum BDNF levels in rodents and they also showed that serum
Table 1. Demographic and clinical characteristics of the study samples (n=40 in each sample).
Healthy controls (n=40) Patients (n=40) P-value
Age in years (mean 6 SD) 38.3567.07 39.5568.66 0.65
Sex (M/F) 21/19 20/20 0.82
SDS score (mean 6 SD) 36.1966.87 59.5664.87 4.21E-22
BDNF (ng/ml, mean 6 SD) 25.2265.17 20.0565.98 7.89E-05
miR-132 (10
3 copies/ml, median) 0.13 0.58 1.96E-04
miR-182 (10
3 copies/ml, median) 0.01 0.02 2.58E-03
SD, standard deviation. SDS, Self-Rating Depression Scale. BDNF, brain-derived neurotrophic factor. P -values are from the Student’s t-test or Wilcoxon rank sum test to
compare patient samples with healthy control samples.
doi:10.1371/journal.pone.0063648.t001
Figure 1. BDNF serum levels and its related miRNAs. (A) BDNF
concentrations in patients and controls. The serum levels of BDNF in the
patients with depression (n=40; 20.0565.98 ng/ml) were significantly
decreased compared with those of the healthy controls (n=40;
25.2265.17 ng/ml). (B) The targeting site on BDNF-mRNA-39UTR by
miR-182, which was aligned with the mRNA-39UTR of human bdnf gene
with the nucleotide position. Vertical lines indicate identity.
doi:10.1371/journal.pone.0063648.g001
Figure 2. miR-132/182 regulating BDNF expression. (A, B)
Detection of BDNF by western blotting. SH-SY5Y cells were treated with
miR-182 or miR-132, the results showed that BDNF expression in the
miR-182- or miR-132-treated cultures was much lower than that of
negative control miRNA cultures. *P,0.05, miR-182- or miR-132-treated
cultures vs. control cultures. Relative values for BDNF vs. Actin are
indicated in Fig.2B.
doi:10.1371/journal.pone.0063648.g002
BDNF-Related miRNAs in Depression
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matched controls [16]. Other reports have also indicated that
serum BDNF levels were lower in drug-free major depressed
subjects than in control subjects [31,32]. Similarly, we found that
serum BDNF levels were lower in patients with depression
compared with controls. We also found that a negative correlation
between BDNF level and SDS score in both patients and controls.
Thus, the above studies suggest that serum BDNF may be a
clinically useful biomarker for depression.
Despite the consistence from many findings showing lower
serum BDNF levels in patients with depression, decreased BDNF
levels have also been found in several other disease, like
Huntington’s disease [33], Alzheimer’s disease [34], schizophrenia
[35], and bipolar disorder [36]. Thus, the apparent lack of
diagnostic specificity in the BDNF levels is likely to be a major
drawback, which limits the true clinical application of this
measure. Therefore, serum BDNF-related miRNAs, combined
with serum BDNF levels, were investigated in this study to increase
the feasibility of applying BDNF-related miRNAs in the diagnosis
of depression. Our study also warrant future studies of the levels of
these BDNF-related miRNA in other mental disorders.
A large number of miRNAs are shown to be specifically
expressed in neuronal and non-neuronal cells in the brain and
enriched in the central nervous system, and their expressions are
regulated at various biological circumstances [24]. miR-124 and
miR-128 are primarily expressed in neurons, whereas miR-23,
miR-26, and miR-29 are expressed in high amounts in astrocytes
[37]. During acute or chronic stress, the expression of miR-134,
miR-183, miR-132, Let-7a-1, miR-9-1, and miR-124a-1 is altered
in a hippocampal region responsible for mood [38]. miR-124 and
cAMP response element-binding protein (CREB) are found to be
involved in a feedback loop contributing to neuronal plasticity
[39], which shows that miR-124 can control serotonin-induced
synaptic facilitation through posttranscriptional suppression of
CREB and, conversely, CREB can further regulate the expression
of miR-124 [40]. Likewise, a similar mechanism has been
identified between BDNF and miR-132, BDNF can dramatically
up-regulate neuronal expression of miR-132 [41], while suppres-
Figure 3. Serum miR-132 and miR-182 levels detected by real-time PCR. (A, B) Serum miR-132 or miR-182 levels in patients with depression
and their controls, respectively. Real-time PCR showed that serum miR-132 (or miR-182) levels in depressed patients (n=40) were much higher than
those in healthy controls (n=40, P,0.01).
doi:10.1371/journal.pone.0063648.g003
Figure 4. Relationship between levels of serum BDNF and its related miRNAs. (A) A significant negative correlation (Spearman rs=20.307,
P=0.006) between the serum BDNF and miR-132 levels in depressed patients (n=40) and controls (n=40). (B) No significant correlation (Spearman
rs=0.098, P=0.385) was found between the serum BDNF and miR-182 levels in depressed patients (n=40) and controls (n=40).
doi:10.1371/journal.pone.0063648.g004
BDNF-Related miRNAs in Depression
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BDNF transcript levels [27]. Similarly, our results demonstrated
that miR-132 treatment in human neuronal cells significantly
decreased the BDNF expression. Thus, these studies indicate that
there may be a feedback loop between the expression of miR-132
and BDNF.
Our study further studied the neurobiological role of miR-132.
MiR-132 is important for enhancing neuronal survival and its
expression is up-regulated in transplanted neurons [42]. miR-132
expression in the murine prefrontal cortex can regulate neuro-
developmental processes, but its dysregulation contributes to the
neuro-developmental pathologies in schizophrenia [43]. Davis
et al. reported that spontaneous cortical levels of miR-132 were
lower at the end of the sleep-dominant light period than those at
the end of the dark period in rats, suggesting that miR-132 played
a regulatory role in sleep [44]. In this study, our results showed
that the serum miR-132 levels were increased in patients with
depression than those in controls, which might contribute to the
lower serum BDNF levels.
We also investigated the biological roles of miR-182 in
depression. miR-182 has been shown to regulate cell growth and
suggested as a tumor-suppressive gene. Dysregulation of miR-182
can result in tumorigenesis, and lead to gastric adenocarcinoma
through a mechanism targeted by CREB1 [45]. Over-expression
of miR-182 expression can regulate cell cycle and suppress
proliferation of lung cancer cells in vitro [46]. However, Bai et al.
reported different roles of miR-182 in non-sonic hedgehog
medulloblastoma, and showed that over-expression of miR-182
contributed to leptomeningeal metastatic dissemination in non-
sonic hedgehog medulloblastoma and the knockdown of miR-182
decreased cell migration in vitro [47]. miR-182 has also been
reported to involve in circadian rhythms in major depression
patients with insomnia [22]. In this study, our results identified and
characterized that miR-182 was a novel putative BDNF regulatory
miRNA in a human neuronal cell model by both bioinformatic
and molecular biological strategies. We also found that the serum
levels of miR-182 were higher in patients with depression
compared with those in healthy controls. The serum levels of
miRNAs (miR-132 and miR-182) were found to be increased and
BDNF levels were reduced in depressed patients compared with
healthy controls, which supported that miR-132 and miR-182
could negatively regulate BDNF expression. Therefore, we found
that a negative correlation between the serum BDNF levels and
the miR-132 levels in depressed patients and healthy controls, but
we did not found a significant negative correlation between the
serum BDNF levels and the miR-182 levels in patients and
controls. The relatively small number of available studies may lead
to this limitation.
In summary, we characterized the roles of BDNF and its related
miRNAs in the pathogenesis of depression and validated that miR-
182 was a novel miRNA that regulated the BDNF levels. Our
results also demonstrated that the serum BDNF levels were
decreased, while the levels of miR-132 and miR-182 were
increased in depressed patients compared with healthy controls.
Our results clearly indicate that BDNF and its related miRNAs
play important roles in the pathogenesis of depression. Further
studies in larger and different subjects are warranted for more
conclusive results.
Materials and Methods
Subjects
This study was performed at the outpatient department of
Psychiatry of Yantai Fushan District People’s Hospital in China.
The research protocol was approved by the Medical Ethics
Committee of Binzhou Medical University. All experiments were
performed in accordance with relevant guidelines and regulations
of the Medical Ethics Committee of Binzhou Medical University.
Prior to inclusion, eligible patients with depression, or their legal
relatives in case of incapacity, provided written informed consent
after study procedures were fully explained.
Chinese classification of mental disorders (CCMD-3) was
performed for diagnosis, which was based on the Clinical
descriptions and diagnostic guidelines of ICD-10. The diagnostic
criteria also refer to the Research Criteria of ICD-10, and the
DSM-IV [48]. Forty patients with depression, aged 23–61 years
old, fulfilled the CCMD-3 criteria for depressive disorder and were
diagnosed with depression first time. They did not take anti-
depression drugs before. A careful diagnostic assessment was
performed to rule out schizophrenia, paranoid psychosis, schizo-
affective disorder, bipolar disorder, organic brain syndrome,
chronic alcohol or drug abuse, and clinically relevant somatic
illness. Then, they were evaluated by Self-Rating Depression Scale
(SDS). SDS is a 20-item self-reported measurement of the
Figure 5. Relationship between serum levels of BDNF-related miRNAs and SDS score. (A) A significant negative correlation (Pearson
r=20.427, P=7.75E-05) was found between serum BDNF levels and SDS score in depressed patients (n=40) and controls (n=40). (B) An obvious
positive correlation (Spearman rs=0.347, P=0.002) was revealed between the serum miR-132 levels and SDS score in patients with depression (n=40)
and controls (N=40). (C) There was an obvious positive correlation (Spearman rs=0.242, P=0.030) between the serum miR-182 levels and SDS score
in depressed patients (n=40) and healthy controls (N=40).
doi:10.1371/journal.pone.0063648.g005
BDNF-Related miRNAs in Depression
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cognitive, psychomotor, somatic, and affective symptoms. Each
item is scored from 1 to 4. The raw score is converted into
standardized score. A cut-off higher than 53 is defined presence of
depression according to the Chinese version of this scale (Zhang
M, Handbook of psychiatry scales. Science and Technology
Publishing Company of Hunan). Forty healthy controls, who came
to Yantai Fushan District People’s Hospital for physical examina-
tion during the period from March 1st, 2010 to September 30th,
2010, were diagnosed without any mental or physical illness. All
the controls provided written informed consent and agreed to
participate in this study after study procedures were fully
explained.
Serum BDNF Detection
Serum samples from the patients with depression and controls
were collected between 8:00 and 9:00 a.m. After centrifugation for
20 min at 2,650 g, serum was stored at 80uC. Serum BDNF was
analyzed in duplicate as follows: The samples were incubated in a
96-well plate, followed by the addition of rabbit anti-human
antibodies against BDNF (SC-546; Santa Cruz Biotechnology,
Santa Cruz, CA) according to the manufacturer’s instructions.
Then antibody binding was detected by incubation with goat anti-
rabbit IgG/HRP-labeled secondary antibodies (1:2000, Beijing
Zhong Shan-Golden Bridge Technology Co., Ltd., China) and
their substrates in turn. The optical density of the reaction was
estimated spectrophotometrically at 450 nm using an ELX800
ELISA reader (Bio-Tek Instrument Inc., USA).
Real-time PCR
The mirVana
TM miRNA isolation kit (Ambion, USA) was used
to extract miRNAs from plasma according to the manufacturer’s
instructions. Then, miRNAs were added ploy (A) using poly (A)
polymerase (Ambion). The cDNAs were synthesized by RT primer
59-AACATGTACAGTCCATGGATGd(T)30N(A,G,C or T)-39,
miR-132 and miR-182 were analyzed by real-time PCR. The
miR-132 forward primer: 59-ACAGTCTACAGCCATGGTC-39.
Reverse primer was 59-AACATGTACAGTCCATGGATG-39.
The miR-182 forward primer was 59-GGCAATGGTAGAACT-
CACACT-39. Reverse primer was 59-AACATGTACAGTC-
CATGGATG -39. Real-time PCR analysis was performed by
SuperTaq Polymerase (Takara, Japan). The expression of
miRNAs was detected using the RG3000 system (Corbett
Research, Austrilia) with the Quantitect SYBRGreen Kit (Qiagen)
as our previous study [49,50]: an initial denaturation at 95uC for
4 min, followed by 40 cycles of 95uC denaturation for 30 s, 52uC
annealing for 30 s, and extension at 72uC for 30 s. Fluorescence
was detected at 585 nm at each extension step of 72uC. Human 5S
rRNA was added into each sample and served as control. All
transfections were performed in triplicate.
Cell Culture and Transfection
Human neuroblastoma cells (SH-SY5Y, obtained from Shang-
hai Institute of Cell Biology, China) were grown in DMEM/F12
medium (Hyclone, USA) containing 10% FCS (Hyclone, USA)
and 100 U/ml of penicillin-streptomycin (Sigma, USA) at 37uC
with 5% CO2.
MiR-132 and miR-182 were chemically synthesized in the form
of small interfering RNA (siRNA) duplexes according to Park’s
study [51] (Table 2). 1610
6 cells were transfected with 0.5 mg
miRNA in 1.5 ml of lipofectamine 2000 (Invitrogen, USA),
according to the manufacturer’s instructions. All transfections
were performed in triplicate.
Western Blotting
Forty-eight hours after transfection, total protein lysates of SH-
SY5Y cells were prepared and each 40 mg protein sample was
loaded onto 10% SDS-PAGE. After electrophoresis, the protein
was transferred to PVDF membrane, which was blocked with 7%
non-fat milk in TBST [50 mmol/L Tris-HCl (pH 7.6),
150 mmol/L NaCl, 0.1% Tween-20] for 1.5 h at room temper-
ature. The TBST buffer solution was added to wash the
membrane 3 times before immunoblotting with polyclonal rabbit
anti-human BDNF antibody (1:400, SC-546; Santa Cruz Biotech-
nology, Santa Cruz, CA). After being incubation at 4uC overnight
and a wash with TBST, the membrane was incubated with a
HRP-labeled goat anti-rabbit IgG (1:4000, Beijing Zhong Shan-
Golden Bridge Technology Co., Ltd, China) for 1 h at room
temperature. The same membrane also was stripped and re-
probed with Actin antibody (1:400, Beijing Zhong Shan-Golden
Bridge Technology Co., Ltd, China) as control. All experiments
were performed in triplicate.
Statistics
Data were first tested for normal distribution and variance
homogeneity with shapiro.test and F test, respectively. If normal
distribution was verified, data were expressed as means 6 SD, or
expressed as median and quartiles. Since BDNF and SDS score
showed normal distribution, differences between these two groups
were analyzed using Student’s t-test and Pearson’s correlation
coefficient was calculated to assess the relationship among
variables. Since miR-132, miR-182 did not showed normal
distribution, nonparametric tests were applied. Differences in
continuous variables (miR-132, miR-182) between groups were
analyzed by Wilcoxon rank sum test, and the correlations were
calculated by the Spearman rank test. Statistical analyses were
performed with R version 2.15.0 (Copyright (C) 2012, ISBN 3-
900051-07-0). For all statistical analyses, P,0.05 was considered
statistically significant.
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Table 2. The sequences of chemically synthesized miRNA
a.
Oligos Sequences (59R39)
miR-132 sense uaacagucuacagccauggucg
antisense cgaccauggcuguagacuguuauu
miR-182 sense uuuggcaaugguagaacucacacu
antisense agugugaguucuaccauugccaaauu
control (scramble
sequence)
sense caguacuuuuguguaguacaa
antisense guacuacacaaaaguacuguu
aThe selected miRNAs were chemically synthesized in the form of small
interfering RNA (siRNA) duplexes.
doi:10.1371/journal.pone.0063648.t002
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